Collegium Pharmaceutical, Inc. Deferred Revenue Recognized
Collegium Pharmaceutical, Inc. (COLL) reported Deferred Revenue Recognized of $166.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-06
- Collegium Pharmaceutical, Inc. contract with customer, liability, revenue recognized for the quarter ending 2026-06-30 was $166.00K.
- Collegium Pharmaceutical, Inc. contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was $167.00K.
- Collegium Pharmaceutical, Inc. contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was $0.00.
- Collegium Pharmaceutical, Inc. contract with customer, liability, revenue recognized for the quarter ending 2018-03-31 was $1.22M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 8 month | Contract with Customer, Liability, Revenue Recognized 9 month |
|---|---|---|---|---|
| 2026-06-30 | $166.00K 10-Q · filed 2026-08-06 | $333.00K 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $167.00K 10-Q · filed 2026-05-07 | |||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $0.00 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 | |||
| 2021-09-30 | $12.96M 10-Q · filed 2022-11-03 | |||
| 2018-03-31 | $1.22M 10-Q · filed 2018-05-09 | |||
| 2017-09-30 | $4.38M 10-K · filed 2019-02-27 | |||
| 2017-06-30 | $1.23M 10-Q · filed 2018-08-08 | $2.45M 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |